Allergan PLC. (NYSE:AGN) – Analysts at Gabelli increased their Q3 2017 EPS estimates for Allergan PLC. in a note issued to investors on Monday. Gabelli analyst K. Kedra now anticipates that the company will post earnings per share of $4.16 for the quarter, up from their prior estimate of $4.09. Gabelli also issued estimates for Allergan PLC.’s Q4 2017 earnings at $4.72 EPS.

Several other research firms have also weighed in on AGN. Mizuho reissued a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company increased their price target on Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG restated a “buy” rating and issued a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target for the company in a report on Monday, June 26th. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $275.49.

TRADEMARK VIOLATION NOTICE: “Q3 2017 EPS Estimates for Allergan PLC. (AGN) Lifted by Gabelli” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/q3-2017-eps-estimates-for-allergan-plc-agn-lifted-by-gabelli.html.

Allergan PLC. (NYSE:AGN) opened at 231.14 on Wednesday. The stock has a market cap of $77.27 billion, a PE ratio of 7.04 and a beta of 1.16. The firm’s 50-day moving average price is $245.03 and its 200 day moving average price is $238.77. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business posted $3.35 EPS.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.21%. Allergan PLC.’s payout ratio is currently 9.95%.

In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.36% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the company. Capital Investment Advisors LLC boosted its stake in Allergan PLC. by 1.0% in the first quarter. Capital Investment Advisors LLC now owns 6,342 shares of the company’s stock valued at $1,515,000 after buying an additional 60 shares during the last quarter. Benson Investment Management Company Inc. boosted its stake in Allergan PLC. by 1.3% in the first quarter. Benson Investment Management Company Inc. now owns 8,779 shares of the company’s stock valued at $2,097,000 after buying an additional 110 shares during the last quarter. Telemus Capital LLC boosted its stake in Allergan PLC. by 208.1% in the first quarter. Telemus Capital LLC now owns 21,012 shares of the company’s stock valued at $5,020,000 after buying an additional 14,193 shares during the last quarter. Farmers & Merchants Investments Inc. boosted its stake in Allergan PLC. by 89.9% in the first quarter. Farmers & Merchants Investments Inc. now owns 29,073 shares of the company’s stock valued at $6,946,000 after buying an additional 13,765 shares during the last quarter. Finally, Reliance Trust Co. of Delaware boosted its stake in Allergan PLC. by 1.2% in the first quarter. Reliance Trust Co. of Delaware now owns 13,292 shares of the company’s stock valued at $3,176,000 after buying an additional 159 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Earnings History and Estimates for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.